Top Markets
Coin of the day
Vincerx Pharma, Inc. Vincerx Pharma, Inc.

Vincerx Pharma, Inc.

VINC
Classement en actions #40889
Vincerx Pharma, Inc. is a biopharmaceutical firm currently in the clinical... Vincerx Pharma, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering and advancing innovative treatments for cancer, specifically addressing areas of high medical need within the U.S. Its primary therapeutic asset is VIP152, an inhibitor targeting cyclin-dependent kinase-9 (CDK9), designed for individuals battling advanced forms of cancer. Beyond this lead candidate, the company's pipeline features several preclinical-stage projects: VIP217, an orally administered PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate aimed at solid tumor treatment; and VIP943 and VIP924, both geared towards treating blood cancers. Established in 2019, Vincerx Pharma is based in Palo Alto, California.
Prix de l'action
$0.0127
Dernière synchronisation: 2026-08-12
Capitalisation boursière
$66.48K
Changement (1 jour)
-2.31%
Changement (1 an)
-67.44%
Pays
US
Échange Vincerx Pharma, Inc. (VINC)

Catégorie

Ratio P/S pour Vincerx Pharma, Inc. (VINC)
Ratio P/S au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Vincerx Pharma, Inc., le ratio cours/ventes actuel (TTM) est 0. À la fin de 2026, le ratio P/S était de 0.
Historique du ratio P/S pour Vincerx Pharma, Inc. de 2026 à 2026
Ratio P/S à la fin de chaque année
Année Ratio P/S Changez
Pas assez de données pour les dates fournies.
Ratio P/S pour des entreprises similaires ou concurrentes
Entreprise Ratio P/S Différence de Ratio P/S Pays
9.88 -
US
10.30 -
NL
- -
CH
- -
KR
4.98 -
BE